FirstIgnite is supporting the commercialization of the University of California, Davis’s new immunotherapeutics for pediatric tumors technology. This technology enhances immunotherapy for solid cancer tumors by targeting multiple cancer cell elimination mechanisms simultaneously. It boosts death receptor activation, enhances TIGIT inhibition, and co-targets cell death and immune checkpoint pathways using a single agent.

This technology is applicable to the treatment of solid tumor cancer cells. The global solid tumor cancer treatment market size was valued at $185.97 billion in 2022 and is expected to reach $532.42 billion by 2032.

The University of California, Davis’s immunotherapeutics for pediatric tumors technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of California, Davis team, you can schedule a time directly on their team’s calendar here.